Benzinga | Jan 20, 2022 08:10AM EST

Olink Holding Announces Sequanta Technologies Will Use Olink Explore 3072 To Analyze 1,000 Patient Samples From A New Cohort Study In China

Olink Holding AB (publ) (NASDAQ:OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based in China, will use Olink(r) Explore 3072 to analyze 1,000 patient samples from a new cohort study in China.

Since 2021, Sequanta and Olink's partnership has provided Sequanta access to Olink's Proximity Extension Assay (PEA) technology. This collaboration has enabled end-to-end multi-omic clinical studies, which could also facilitate the development of precision medicine in China. As Olink's preferred third-party service provider in China, Sequanta is serving pharmaceutical and academia customers in this geography, utilizing Olink's innovative and disruptive technology, particularly in high-throughput multi-omics research based on genomics, transcriptomics, and proteomics.

"We have seen strong local demand in the past year, demonstrated by clear market interest and the significant number of contracts signed by Sequanta with prestigious research institutions and biopharmaceutical companies," said Lele Sun, PhD, Founder and CEO at Sequanta. "In this new program, Sequanta will use the Olink(r) Explore 3072 high-throughput proteomics platform to analyze over 1,000 human samples from a large-scale cohort study for the investigation of novel markers and therapeutic targets in common chronic diseases in collaboration with one of the top universities in China."

"After years of customer requests for Olink's pioneering technology, we are very excited to also see growing demand from our customers in China in the expansion of our protein biomarker library with Olink(r) Explore 3072," said Andrea Ballagi, MD, PhD, Vice President Sales and Marketing Asia and Pacific Region, Olink Proteomics. "The fast-growing proteomics field is expected to play an increasingly important role in human health, and we're looking forward to working with Sequanta to address the needs of this market."